Gilgamesh Pharmaceuticals vs GE HealthCare
Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical-stage psychedelic pharma developing novel psilocybin-derived bretisilocin in Phase 2 for depression; first YC-backed psychedelics company competing with COMPASS Pathways.
About
Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company developing novel psychedelic-derived compounds for treatment-resistant depression, anxiety, and stress-related psychiatric disorders — pursuing a drug discovery approach that modifies psychedelic molecular structures to optimize therapeutic effects (efficacy, duration) while retaining or modifying the subjective psychedelic experience. Founded by Jonathan Sporn MD, Dalibor Sames PhD, Andrew Kruegel PhD, Jeff Witkin PhD, and Mike Cunningham PhD, Gilgamesh was the first Y Combinator-backed company in the psychedelic therapeutics space.\n\nGilgamesh's lead compound bretisilocin (GM-2505) is a novel psilocybin-derived molecule in Phase 2 clinical trials for major depressive disorder, positioned as a potential best-in-class psychedelic compound with optimized pharmacokinetics. The company's scientific founders from Columbia University brought expertise in psychedelic pharmacology and medicinal chemistry that enables rational drug design rather than simply repurposing existing natural psychedelics like psilocybin. The differentiated compound IP strategy creates defensible pharmaceutical assets rather than relying on natural compound exclusivity.\n\nIn 2025, Gilgamesh competes in the psychedelic medicine market with COMPASS Pathways (psilocybin for treatment-resistant depression, furthest along in clinical trials), Usona Institute (psilocybin non-profit research), MindMed (LSD and MDMA derivatives), and Lykos Therapeutics (MDMA-assisted therapy) for psychedelic-derived psychiatric treatment development. The FDA declined to approve MDMA-assisted therapy in 2024 (Lykos), creating caution around psychedelic clinical timelines, while COMPASS continues Phase 3 trials for psilocybin. Gilgamesh's novel compound approach (not psilocybin itself) provides a distinct regulatory and IP path. The 2025 strategy focuses on Phase 2 data readouts for bretisilocin, building clinical evidence for the compound's differentiated profile, and advancing toward a Phase 3 pivotal trial design.
Chicago medical imaging and AI diagnostics (NASDAQ: GEHC) ~$19.7B FY2024 revenue; GE spinoff Jan 2023, Edison AI 100+ models, 4M+ installed devices, Alzheimer's PET tracer competing with Siemens Healthineers.
About
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designing, manufacturing, and servicing medical imaging systems, patient monitoring equipment, pharmaceutical diagnostics, and AI-powered clinical decision support software through approximately 51,000 employees in 160 countries. GE HealthCare was spun off from General Electric Company in January 2023 — one of the most significant healthcare demergers in history — and has operated as an independent public company building its own capital structure, R&D investment priorities, and operational identity separate from GE's industrial conglomerate structure. In fiscal year 2024, GE HealthCare reported revenues of approximately $19.7 billion, with its four business segments contributing: Imaging (MRI, CT, X-ray, molecular imaging — ~$9.1B), Ultrasound (~$3.0B), Patient Care Solutions (monitoring, anesthesia — ~$3.6B), and Pharmaceutical Diagnostics (PET/SPECT contrast agents — ~$2.6B). CEO Peter Arduini has prioritized accelerating GE HealthCare's AI integration across its imaging portfolio — the Edison AI platform (100+ AI models cleared or in development for radiology workflows) embeds AI-assisted detection, workflow optimization, and image quality enhancement into GE HealthCare scanners, positioning the company as a digital health platform rather than a hardware manufacturer.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.